Position in ENTA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,757,295
New position
Shares Held
257,702
first reported quarter
Ownership
0.885%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#21
of 122 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026SummitTX Capital, L.P. holds $220,272,212 across 62 Biotechnology names. ENTA ranks #23 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
126,401 | $14,034,303 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
374,270 | $12,496,875 | |
| 3 | CYTK |
Cytokinetics Inc
|
112,893 | $9,617,354 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
254,959 | $9,487,024 | |
| 5 | QTTB |
Q32 Bio Inc.
|
733,774 | $9,348,280 | |
| 6 | GMAB |
Genmab A/S
|
318,408 | $8,746,667 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
36,276 | $8,741,427 | |
| 8 | ABVX |
Abivax S.A.
|
65,216 | $8,690,684 |
All Filings in ENTA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,757,295 | 257,702 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||